New antibody cocktail aims to stop rabies after multiple dog bites
NCT ID NCT07624461
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether a new antibody injection, called zamerovimab and mazorelvimab, combined with the standard rabies vaccine, can prevent rabies in people who have been severely bitten by a dog. The trial follows 80 adults in China for up to one year to see if they stay rabies-free. The goal is to improve protection after high-risk exposures.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
zamerovimab and mazorelvimab injection (a human rabies antibody cocktail) plus rabies vaccine
What this could lead to
If successful, this could offer a more effective way to prevent rabies after severe dog bites, potentially saving lives in areas where rabies is common.
What could go wrong
This is a small, early real-world study with only 80 participants, so results may not apply to everyone. The treatment might not prevent rabies in all cases, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RABIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Disease Prevention and Control Center of Nanyang
Nanyang, Henan, 473000, China